A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine

Trial Profile

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 07 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 7 Feb 2017.
    • 11 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top